Skip to main content

News

Opinion: The other shoe drops: Gilead's outrageous pricing of remdesivir

By Forbes  
   June 29, 2020

Gilead says it will charge governments $2,340 and private insurers $3,120 for a 5-day course of remdesivir, a treatment for Covid-19 patients. This is an outrageous price for a drug that has demonstrated little to no ability to save lives or lower viral loads in patients.

Full story


Get the latest on healthcare leadership in your inbox.